Nomura Holdings’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $410K | Sell |
2,432
-1,768
| -42% | -$262K | ﹤0.01% | 1559 |
|
|
2026
Q1 | $553K | Sell |
4,200
-3,310
| -44% | -$439K | ﹤0.01% | 1331 |
|
|
2025
Q4 | $1.07M | Sell |
7,510
-1,641
| -18% | -$238K | ﹤0.01% | 1315 |
|
|
2025
Q3 | $1.28M | Buy |
+9,151
| New | +$1.24M | ﹤0.01% | 1314 |
|
|
2025
Q1 | – | Sell |
-13,434
| Closed | -$1.83M | – | 2175 |
|
|
2024
Q4 | $1.83M | Buy |
+13,434
| New | +$1.66M | ﹤0.01% | 1172 |
|
|
2024
Q3 | – | Sell |
-1,700
| Closed | -$233K | – | 1838 |
|
|
2024
Q2 | $234K | Buy |
+1,700
| New | +$233K | ﹤0.01% | 1561 |
|
|
2022
Q4 | – | Sell |
-9,000
| Closed | -$956K | – | 1615 |
|
|
2022
Q3 | $956K | Buy |
+9,000
| New | +$913K | ﹤0.01% | 970 |
|
|
2022
Q1 | – | Sell |
-4,500
| Closed | -$381K | – | 2265 |
|
|
2021
Q4 | $383K | Buy |
+4,500
| New | +$414K | ﹤0.01% | 1614 |
|
|
2021
Q2 | – | Sell |
-12,000
| Closed | -$1.17M | – | 2233 |
|
|
2021
Q1 | $1.17M | Buy |
+12,000
| New | +$1.26M | ﹤0.01% | 1035 |
|
|
2020
Q4 | – | Sell |
-38,000
| Closed | -$3.65M | – | 1608 |
|
|
2020
Q3 | $3.65M | Buy |
+38,000
| New | +$4.4M | 0.01% | 535 |
|
|
2020
Q2 | – | Sell |
-8,771
| Closed | -$969K | – | 1216 |
|
|
2020
Q1 | $761K | Buy |
8,771
+218
| +3% | +$21.3K | ﹤0.01% | 609 |
|
|
2019
Q4 | $919K | Sell |
8,553
-21,947
| -72% | -$2.3M | ﹤0.01% | 815 |
|
|
2019
Q3 | $2.73M | Buy |
30,500
+27,000
| +771% | +$2.52M | 0.01% | 589 |
|
|
2019
Q2 | $297K | Sell |
3,500
-54,168
| -94% | -$4.45M | ﹤0.01% | 1004 |
|
|
2019
Q1 | $5.12M | Sell |
57,668
-7,998
| -12% | -$668K | 0.02% | 448 |
|
|
2018
Q4 | $4.68M | Buy |
65,666
+9,479
| +17% | +$908K | 0.02% | 522 |
|
|
2018
Q3 | $6.99M | Buy |
56,187
+17,148
| +44% | +$1.95M | 0.02% | 429 |
|
|
2018
Q2 | $3.83M | Sell |
39,039
-2,243
| -5% | -$201K | 0.01% | 567 |
|
|
2018
Q1 | $3.42K | Buy |
41,282
+25,400
| +160% | +$2.14M | 0.01% | 680 |
|
|
2017
Q4 | $1.23M | Sell |
15,882
-16,000
| -50% | -$1.09M | ﹤0.01% | 1047 |
|
|
2017
Q3 | $1.95M | Buy |
31,882
+21,750
| +215% | +$1.15M | ﹤0.01% | 857 |
|
|
2017
Q2 | $466K | Buy |
+10,132
| New | +$491K | ﹤0.01% | 1248 |
|
|
2017
Q1 | – | Sell |
-9,031
| Closed | -$350K | – | 1503 |
|
|
2016
Q4 | $350K | Sell |
9,031
-39
| -0.4% | -$1.76K | ﹤0.01% | 1314 |
|
|
2016
Q3 | $461K | Buy |
+9,070
| New | +$452K | ﹤0.01% | 915 |
|
|
2013
Q3 | – | Sell |
-50,400
| Closed | -$672K | – | 2514 |
|
|
2013
Q2 | $672K | Buy |
+50,400
| New | +$619K | 0.01% | 1162 |
|
Other funds holding NBIX
Nomura Holdings's NBIX Position: Q2 2026 in Review
Nomura Holdings reduced its Neurocrine Biosciences (NBIX) stake by 42% in Q2 2026, selling an estimated $262K and leaving 2,432 shares worth $410K. The position accounts for ﹤0.01% of the portfolio, ranked #1559.
Nomura Holdings first reported a position in NBIX in Q2 2013 and has held it in 25 quarters since. The position peaked at $6.99M in Q3 2018. 733 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Nomura Holdings held 2,432 shares of Neurocrine Biosciences worth $410K as of Q2 2026.
- Nomura Holdings sold 1,768 Neurocrine Biosciences shares in Q2 2026, an estimated $262K.
- Neurocrine Biosciences made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #1559 holding.
- Nomura Holdings first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 25 quarters since.
- Nomura Holdings's Neurocrine Biosciences position peaked at $6.99M in Q3 2018.
- 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.